Solara Active Pharma Sciences Ltd

- There is no specific mention of any new fundraising through debt or equity in the provided transcript. - The company expects only a marginal reduction in net debt for FY '24, around 10%, indicating no major debt raising plans. - Funds generated will be balanced between debt reduction and capital allocation for growth, suggesting prudent capital management without new large-scale fundraising. - The focus is on improving cash flows and preserving funds to support growth initiatives rather than increasing debt. - Overall, the discussions point towards managing existing debt and capital efficiently rather than pursuing new debt or equity fundraising in the near term.

- Maintenance Capex: Expected to be around INR 70-80 crores per year for compliance across plants. - Growth Capex: Most growth investments for the Vizag facility are already made; current focus is on better capacity utilization rather than new capex. - Vizag Facility: Qualification of customers ongoing, with substantial capacity utilization improvement expected from H2 FY '24; Q4 FY '24 capacity utilization targeted over 60%. - Funds Allocation: Net debt reduction planned to be marginal (~10%) as generated funds will be balanced between debt reduction and capital growth. - Strategic Focus: Continued investment in R&D for new product filings and CRAMS business expansion, aiming for improved product mix and sustainable growth. - Overall, capex is largely completed with emphasis on optimizing existing assets and incremental maintenance spend.

- Growth in top line for FY '24 and FY '25 is expected to be similar to or better than FY '23 (14% growth in FY '23). - Revenue and EBITDA are anticipated to improve year-on-year in FY '24. - Major revenue growth is expected from enhanced capacity utilization at the Vizag facility, particularly in the second half of FY '24. - New product filings and approvals will contribute to commercial revenues starting in the second half of FY '25. - Focus on expanding product mix with quality R&D filings and commercialization over 2-3 years supports sustained growth. - CRAMS business is expected to see significant growth in FY '25 and FY '26, contributing higher gross margins. - Overall, the company aims to return to historical growth levels and improve both revenue and profitability through execution of key strategic focus areas.

- The company expects growth in top line and EBITDA in FY '24 and FY '25 to be in line with or better than FY '23 performance. - FY '23 saw a 14% revenue growth and a 63% increase in reported EBITDA, with a margin of 15.5%. - EBITDA margin is anticipated to improve gradually, targeting the "high teens" and aiming to return to historical levels around 20% by FY '25. - Growth drivers include ramping up capacity utilization at the Vizag facility (expected >60% in Q4 FY '24), expanding the product mix, new product launches, and CRAMS business growth (significant margins expected FY '25/FY '26). - Strategic focus areas are growing existing business, new products, cost improvement, backward integration, and enhanced capacity utilization. - Management remains confident about sustainable earnings growth and margin improvement over the medium term.

- The company has started receiving orders, indicating active demand. - Substantial jump in requirement is expected in the next financial year. - Current orders are primarily from the Pondy facility. - Vizag facility is being qualified as an additional site to handle orders. - There are 11 new pending approvals from the Cuddalore site, which once cleared will trigger new product orders. - New products filed from Vizag are expected to enter validation and commercialization phases in 2 to 3 years. - Overall, order momentum is expected to increase with enhanced capacity utilization and new product filings.